Xeris Biopharma Holdings, Inc. filings document the company’s commercial biopharmaceutical operations, financial results and governance as a Nasdaq-listed issuer. Its Form 8-K reports furnish quarterly and annual operating results, business highlights, financial guidance and product-related updates for Recorlev®, Gvoke® and Keveyis®.
The filing record also includes disclosure of Recorlev patent litigation under the Hatch-Waxman Act, involving Orange Book-listed patents and ANDA-related challenges. Proxy materials cover board composition, executive compensation, equity awards, shareholder voting matters and governance practices, while current reports document board changes and compensatory arrangements.
Xeris Biopharma Holdings is changing its board structure and adding new expertise. The Board increased its size from seven to eight members and appointed Nerissa Kreher, M.D. as a Class III director, effective July 1, 2026, with a term running to the 2027 annual meeting. In connection with her appointment, she received an initial equity award of stock options and restricted stock units with a combined grant date fair value of about $450,000, and she will be eligible for annual equity awards of about $300,000 starting with the 2027 annual meeting, under the non-employee director compensation program.
The Board also named Chief Executive Officer John Shannon as Chairperson of the Board, effective July 1, 2026, and designated Marla S. Persky as Lead Independent Director. These moves consolidate leadership at the CEO level while maintaining a defined independent leadership role on the board.
Xeris Biopharma Holdings entered into privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028. The company will retire approximately $23 million in aggregate principal amount of these notes in exchange for $23 million in cash plus shares of common stock, with the share amount based on the 21‑day volume‑weighted average price starting June 11, 2026.
The company expects the exchange to close on or about July 15, 2026, funded with existing liquidity. Following the exchange, $10.5 million principal of the notes will remain outstanding. A related press release states this will eliminate about $23 million of debt and reduce annual interest expense by roughly $2 million, and, assuming a share price of $6.71, Xeris estimates issuing about 4.6 million shares.
Xeris Biopharma Holdings, Inc. director Garheng Kong reported receiving new equity awards as part of his compensation. He was granted 24,193 shares of common stock in the form of restricted stock units under the company’s 2018 Stock Option and Incentive Plan. Following this award, his direct common stock holdings total 238,337 shares.
He also received a stock option for 32,996 shares of common stock with an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock units and the stock options vest in full on the earlier of June 4, 2026 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through the vesting date.
Xeris Biopharma Holdings director Marla Persky reported both equity awards and a share sale. On June 4, 2026, she received 24,193 shares of Common Stock via a restricted stock unit grant that vests in full on the earlier of June 4, 2026 or the company’s next annual stockholders meeting, subject to continued service.
She also received 32,996 stock options with an exercise price of $6.15 per share, vesting on the same schedule and expiring on June 4, 2036. A day earlier, on June 3, 2026, she sold 15,500 shares of Common Stock in open-market transactions at a weighted average price of $5.8989 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 150,693 shares held directly after the awards. The filing also shows 6,370 shares held indirectly through the Marla Susan Persky Revocable Trust, with beneficial ownership disclaimed except to the extent of pecuniary interest.
Xeris Biopharma director Dawn Halkuff reported a mix of equity grants and a pre-planned share sale. She received 24,193 shares of common stock as a restricted stock unit grant and 32,996 stock options at $6.15 per share, both vesting in full on the earlier of June 4, 2026 or the company’s next annual stockholder meeting, subject to continued service. On the same date, she sold 20,000 shares of common stock at a weighted average price of $6.0943 per share under a Rule 10b5-1 trading plan adopted on September 4, 2025, and held 95,000 shares directly afterward. She also had 5,410 shares held indirectly through the Dawn Halkuff Revocable Trust, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Xeris Biopharma Holdings director Barbara-Jean Anne Bormann-Kennedy reported a mix of equity awards and a stock sale. She received 24,193 shares of common stock as a restricted stock unit grant under the company’s 2018 Stock Option and Incentive Plan, at no cash cost.
She also received stock options for 32,996 shares of common stock at an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock and the options vest in full on the earlier of June 4, 2026 or the company’s next annual meeting of stockholders, subject to continued service.
On the same date, she sold 16,000 shares of common stock in an open-market transaction at a weighted average price of $6.0942 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025. After these transactions, she holds 150,693 common shares directly.
Xeris Biopharma Holdings director John Johnson reported a mix of equity awards and a pre-planned share sale. He received 24,193 shares of common stock through a restricted stock unit grant and 32,996 stock options with a $6.15 exercise price, both vesting in full on the earlier of June 4, 2026 or the company’s next annual stockholder meeting, subject to continued service.
On the same date, he sold 15,000 common shares at a weighted average price of $6.0948 per share under a Rule 10b5-1 trading plan adopted on August 13, 2025. After these transactions, he directly holds 707,276 common shares and 32,996 stock options.
Xeris Biopharma Holdings director Brady James Aloysius received new equity awards. He was granted 24,193 shares of common stock through restricted stock units under the 2018 Stock Option and Incentive Plan, bringing his direct holdings to 113,359 shares.
He was also granted stock options for 32,996 shares of common stock at an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock units and options vest in full on the earlier of June 4, 2026 or the company’s next annual meeting of stockholders, subject to his continued service.
Xeris Biopharma Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 172,625,762 common shares entitled to vote as of April 14, 2026, 128,268,073 were represented, establishing a quorum. Stockholders elected Class II directors Dawn Halkuff and John Johnson by plurality vote.
They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers under the Say‑on‑Pay Vote. No other matters were submitted for stockholder action.